Prospective Molecular Monitoring of Minimal Residual Disease After Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma

Blood - United States
doi 10.1182/blood.v124.21.44.44
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

Minimal Residual Disease Testing After Stem Cell Transplantation for Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2015English

Flow Cytometry in the Diagnosis and Monitoring of Minimal Residual Disease in Multiple Myeloma

Oncogematologiya
OncologyHematology
2017English

Monitoring of Minimal Residual Disease in Multiple Myeloma After Allo-Sct: Flow Cytometry vs PCR-based Techniques

Bone Marrow Transplantation
TransplantationHematology
2008English

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Recurrent Plasmacytomas After Allografting in a Patient With Multiple Myeloma

Case Reports in Medicine
Medicine
2012English

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma

JAMA Oncology
Cancer ResearchOncology
2017English

Serological Normalisation as a Surrogate Marker for Minimal Residual Disease Negativity in Multiple Myeloma

British Journal of Haematology
Hematology
2018English

The Utility of Non-Invasive Liquid Biopsy for Mutational Analysis and Minimal Residual Disease Assessment in Extramedullary Multiple Myeloma

British Journal of Haematology
Hematology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy